Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
AssigneeMacroGenics, Inc.
InventorsLeslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
Claims21
1-27. (canceled)
An antibody conjugate comprising an antibody or an immunoreactive fragment thereof linked to a therapeutic agent, wherein said antibody or said fragment thereof comprises a variable domain that specifically binds an extracellular domain of B7-H3 and comprises:
- (A) a light chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 21, 23 and 25 and a heavy chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 29, 31 and 33;
- or
- (B) a light chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 5, 7 and 9 and a heavy chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 13, 15 and 17;
- or
- (C) a light chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 37, 39 and 41 and a heavy chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 45, 47 and 49.
A method for the treatment of cancer in a patient comprising administering to said patient a therapeutically effective amount of an antibody conjugate, said antibody conjugate comprising an antibody or an immunoreactive fragment thereof linked to a therapeutic agent, wherein said antibody or said fragment thereof comprises a variable domain that specifically binds an extracellular domain of B7-H3 and comprises:
- (A) a light chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 21, 23 and 25 and a heavy chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 29, 31 and 33;
- or
- (B) a light chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 5, 7 and 9 and a heavy chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 13, 15 and 17;
- or
- (C) a light chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 37, 39 and 41 and a heavy chain variable domain that comprises the amino acid sequences of SEQ ID NOs:
- 45, 47 and 49.
Dependencies are inferred from the claim text.